Porton Biopharma Ltd (PBL) has today announced that it has signed a modification to its contract with the US National Institute of Health’s National Institute of Allergy and Infectious Diseases (NIAID) to advance a next generation intra-nasal anthrax vaccine. The contract modification is worth US$5.6 million.
We have opened a brand new suite of office accommodation that will bring together members of Quality Assurance (QA) and other departments into one integrated set of buildings, which will both improve efficiency and also demonstrates the investment that we are making in the company.
Porton Biopharma Limited has been working to support Ohara Pharmaceutical Co. Ltd. who have today announced that they have obtained marketing approval for Erwinase® from the Ministry of Health Labour and Welfare in Japan.
PBL will be active at a number of international conferences this autumn. For more details or to arrange a meeting with us please see the details here, or contact us via email.
PBL have appointed Amir Malik as finance director to assist with strategic planning and direction. Amir has almost 20 years experience in a range of strategic finance roles, is a qualified chartered accountant, has an MBA in finance and a BSc in Chemistry, and brings a wealth of experience of working in both the public and private sectors
Our latest cohort of staff have been independently assessed and achieved a whole series of level 2 and 3 NVQ awards, the awards are in subjects including storage & warehousing and laboratory skills.
In a “ground breaking ceremony” led by Baroness Scott of Bybrook OBE, Porton Biopharma Ltd (PBL) has begun the construction of a new pharmaceutical development facility which will provide state-of–the–art facilities for its teams of scientists.
We are pleased to announce that we have appointed Nigel Brooksby as a new Non Executive Director to the PBL Board. Nigel will take up his position from June and brings to the Board his considerable knowledge and experience in biopharmaceuticals and life-sciences.